EUVIMEDEUVIMED entdecken
Crossref

Bleeding risk of atezolizumab-bevacizumab during ongoing endoscopic variceal ligation in hepatocellular carcinoma: a two-centre retrospective study

G Rahe, S Wiener, F Artusa, G Konstantis, A Zeller, C Schramm, H Schmidt, J Best, F Tacke, R Mohr, L Jochheim

Endoscopy · 01.06.2026 · 58 (S 03 S 03) · S378-S379

DOI: 10.1055/s-0046-1821300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.06.2026. Verfasst von G Rahe und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The combination of atezolizumab and bevacizumab is an established first-line therapy for unresectable hepatocellular carcinoma (HCC). However bevacizumab is associated with an increased risk of gastrointestinal bleeding; in IMbrave150, upper GI bleeding occurred in ~7% of patients, leading to guideline recommendations for pre-treatment endoscopy and primary prophylaxis of oesophageal varices. Many centres therefore defer bevacizumab until endoscopic variceal eradication, delaying full systemic therapy. Two tertiary centres instead adopted an upfront bevacizumab strategy with endoscopic variceal ligation (EVL) in parallel. We aimed to assess the safety and feasibility of this approach in a real-world setting [ 1 ].

Methods

This retrospective two-centre cohort included 354 consecutive Patients (290 males, 81,9%; 63 females, 17,8%, mean age 65.7 years) with HCC treated with atezolizumab-bevacizumab between 2020 and 2024. The primary endpoint was any variceal bleeding with EVL before bevacizumab initiation compared with a non-upfront ligation group. Cox regression was used to assess the association between EVL and variceal bleeding, adjusting for variceal grade, Child–Pugh score and macrovascular invasion.

Results

Overall, 15 variceal bleeding events occurred after bevacizumab initiation (4.2%), of which 10 occurred during therapy (2.8%) and 5 later than 6 months after treatment start (1.4%). In the varices subcohort (n=145 with documented baseline varices), 57/145 (39.3%) patients underwent endoscopic variceal upfront ligation before therapy inititiation, whereas 88/145 (60.7%) did not. Patients who underwent upfront ligation therapy were substantially more likely to have higher-grade varices (grade II/III), whereas the no-ligation group predominantly had grade I varices (p

Zitieren

APA

Rahe, G., Wiener, S., Artusa, F., Konstantis, G., Zeller, A., Schramm, C., Schmidt, H., Best, J., Tacke, F., Mohr, R., & Jochheim, L. (2026). Bleeding risk of atezolizumab-bevacizumab during ongoing endoscopic variceal ligation in hepatocellular carcinoma: a two-centre retrospective study. Endoscopy, 58(S 03 S 03), S378-S379. https://doi.org/10.1055/s-0046-1821300

Vancouver

Rahe G, Wiener S, Artusa F, Konstantis G, Zeller A, Schramm C, et al. Bleeding risk of atezolizumab-bevacizumab during ongoing endoscopic variceal ligation in hepatocellular carcinoma: a two-centre retrospective study. Endoscopy. 2026;58(S 03 S 03):S378-S379. doi:10.1055/s-0046-1821300

BibTeX
@article{Rahe2026,
  author = {Rahe, G and Wiener, S and Artusa, F and Konstantis, G and Zeller, A and Schramm, C and Schmidt, H and Best, J and Tacke, F and Mohr, R and Jochheim, L},
  title = {Bleeding risk of atezolizumab-bevacizumab during ongoing endoscopic variceal ligation in hepatocellular carcinoma: a two-centre retrospective study},
  journal = {Endoscopy},
  year = {2026},
  volume = {58},
  number = {S 03 S 03},
  pages = {S378--S379},
  doi = {10.1055/s-0046-1821300}
}
Kostenlos starten →